ARRIVENT BIOPHARMA, INC. Increase (Decrease) in Accounts Payable, Trade
ARRIVENT BIOPHARMA, INC. (AVBP) reported Increase (Decrease) in Accounts Payable, Trade of -$3.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$6.51M.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $2.81M, a 382.30% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$8.00K.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $1.87M, a 124.10% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accounts payable, trade for fiscal 2025 was $2.14M.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accounts payable, trade for fiscal 2024 was -$751.00K, a 154.46% decline from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was $1.38M.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$3.70M 10-Q · filed 2026-08-12 | -$3.71M derived: sum of 3 quarters · filed 2026-08-12 | -$1.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.81M 10-Q · filed 2026-05-11 | $2.80M derived: sum of 2 quarters · filed 2026-05-11 | $4.67M derived: sum of 3 quarters · filed 2026-05-11 | $4.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.86M derived: sum of 2 quarters · filed 2026-03-05 | $1.56M derived: sum of 3 quarters · filed 2026-08-12 | $2.14M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.57M derived: sum of 2 quarters · filed 2026-08-12 | $2.15M 10-Q · filed 2025-11-10 | $1.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $280.00K 10-Q · filed 2026-08-12 | -$585.00K derived: sum of 3 quarters · filed 2026-08-12 | $249.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $582.00K 10-Q · filed 2026-05-11 | -$283.00K derived: sum of 2 quarters · filed 2026-05-11 | $551.00K derived: sum of 3 quarters · filed 2026-05-11 | $205.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$865.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$31.00K derived: sum of 2 quarters · filed 2026-03-05 | -$377.00K derived: sum of 3 quarters · filed 2026-03-05 | -$751.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $834.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $488.00K derived: sum of 2 quarters · filed 2025-11-10 | $114.00K 10-Q · filed 2025-11-10 | $409.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$346.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$720.00K 10-Q · filed 2025-08-11 | -$425.00K derived: sum of 3 quarters · filed 2025-08-11 | -$2.65M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$374.00K 10-Q · filed 2025-05-12 | -$79.00K derived: sum of 2 quarters · filed 2025-05-12 | -$2.31M derived: sum of 3 quarters · filed 2025-05-12 | $1.39M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.94M derived: sum of 2 quarters · filed 2025-03-03 | $1.76M derived: sum of 3 quarters · filed 2025-03-03 | $1.38M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.46M derived: sum of 2 quarters · filed 2024-11-14 | $1.08M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.31M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$380.00K 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |